Stock AVCT AVACTA GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Market Closed - London S.E.
Other stock markets
 11:35:17 2024-06-14 am EDT 		5-day change 1st Jan Change
40.25 GBX +0.62% Intraday chart for Avacta Group Plc -1.83% -65.45%
May. 23 Windward wins deal; Kodal progresses at Bougouni AN
May. 23 Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial CI

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
AVACTA GROUP PLC Stock Avacta Group Plc
-65.45% 182M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.15% 124B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.02% 112B
B+
ARGENX SE Stock argenx SE
+5.07% 22.94B
B
BIONTECH SE Stock BioNTech SE
-12.75% 22.22B
B+
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.86% 17.02B
B
GENMAB A/S Stock Genmab A/S
-14.97% 16.88B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.94% 16.87B
A-
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.80% 13.63B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.39% 11.61B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AVCT Stock
  4. Ratings Avacta Group Plc